The Amifostine Hydrate market was valued at USD50.4 Mn by 2019. As per the latest research citings presented by the World Health Organization (WHO), cancer is the second leading cause of death worldwide occurring in about 1 in 6th individuals throughout the globe. Amifostine Hydrate is critical in reducing the nephrotoxicity and xerostomia associated with chemotherapy and radiation therapy. It is the most popular adjuvant therapy prescribed by oncologists owing to its cytoprotective activity.

Amifostine hydrate is available as a single dose vial of 500mg intended for intravenous administration, it needs to be reconstituted with 9.7 ml of sodium chloride (0.9%) injection. The reconstituted mixture is stable for 5 hours at room temperature and 24 hours if kept in a refrigerator. It needs to be given 30 minutes prior to chemotherapy and the blood pressure needs to be constantly monitored every 5 minutes during the infusion. The recommended dose to reduce cumulative renal toxicity is 910 mg/m2 once every day as a 15 minutes infusion, it needs to be given 30 minutes prior to chemotherapy and the blood pressure needs to be constantly monitored every 5 minutes during the infusion. The recommended dose for xerostomia is 200 mg/m2once every day as a 3-minute infusion usually 15 minutes before radiation therapy.

The major segments related to the Amifostine Hydrate market are:

By Indication (2017–2027; US$ Mn)

Cumulative Renal Toxicity

Xerostomia

By End User (2017–2027; US$ Mn)

Hospitals & Clinics

Rehabilitation Centers

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global Amifostine Hydrate market
• The overall segmentation of the Amifostine Hydrate market, by indication, end-user, and geography is minutely studied. Cumulative renal toxicity and hospitals & clinics are dominating the indication and end-user segments respectively
• Constant rise in patients receiving cisplatin treatment for ovarian cancer eventually resulting in nephrotoxicity drive the Amifostine Hydrate market growth
• An increasing number of patients receiving radiation therapy for neck surgery eventually resulting in xerostomia further consolidates the Amifostine Hydrate market growth

Report gist?

• The study of the global Amifostine Hydrate market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and end-user and categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 considering 2019 as the base year for the research. CAGR for each respective segments are calculated for the forecast period from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical and contract manufacturing organization engaged in manufacturing and marketing of Amifostine Hydratewhich is gaining huge demand owing to increasing demand for its cytoprotective ability in patients suffering with nephrotoxicity and xerostomia
• The report will benefit oncologist engaged in prescribing adjuvant drug treatment in patient’s suffering with ovarian and head & neck cancer
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to Amifostine Hydrate market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

As per the research citings presented by the European Society for Medical Oncology (ESMO) the head and neck cancer is the 6th most malignant type of cancer throughout the world. The majority of the patients opt for radiation therapy which eventually results in xerostomia. Cumulative renal toxicity is the fastest-growing segment for the Amifostine hydrate market. According to the research citings brought forward by the World Cancer Research Fund in 2018, approximately 300,000 new cases of ovarian cancer in women were reported worldwide. Repeated chemo cycles of cisplatin is administered by intravenous injection in patients suffering from ovarian cancer. Nephrotoxicity occurs as an adverse effect associated with cisplatin chemotherapy. Amifostine hydrate is used as an adjuvant therapy due to its cytoprotective activity on the healthy renal cells.

Hospitals and clinics are currently leading the end-user segment for the Amifostine hydrate market. The significant rise in inpatient admission due to a concomitant increase in the number of new cancer diagnosed patients. Availability of Amifostine hydrate injection at a subsidized price in government-funded cancer hospitals & clinics worldwide. Rehabilitation centers have gained tremendous traction in the last decade on account of its ability to prevent distress and mental strain in patients receiving chemotherapy and radiation therapy which is associated with severe side effects. Rehabilitation centers are critical in restoring physical and mental health in patients undergoing cancer treatment.

North America is spearheading the geography segment for the Amifostine Hydrate market. As per the latest statistics provided by the Ovarian Cancer Research Alliance in 2019, the estimated number of new cases of ovarian cancer is 22,530 in the United States. The rising prevalence of cumulative renal toxicity associated with cisplatin therapy in patients suffering from ovarian cancer primarily determines the Amifostine Hydrate market growth in North America. Affordable reimbursement scenario associated with the generic injection of Amifostine Hydrate further accentuates its market growth in the region. According to the latest research citings brought forward by the European Society for Medical Oncology (ESMO) the annual incidence rate associated with head and neck cancer in the European region is 43 per 100,000 people. Rising prevalence of xerostomia in patients receiving radiation therapy for head and neck cancer determines the Amifostine market growth in Europe. It is anticipated that the Asia Pacific is set to record rampant market growth in the near future on account of the significant rise in the medical tourism industry and the presence of a huge generic drug market.